Yinming Bio's new CAR-T product announces clinical data, HKP1 inhibitor is approved for clinical use

On February 14, Yinming Bio announced that its research on HPK1 targets has recently achieved two new breakthroughs

According to the press release, HPK1 is an important target in tumor immunity.

Among them, XYF19 is a new CD19 CAR-T cell therapy product, which is produced based on the technology platform for reducing the expression of HPK1 protein in T cells developed by Xi'an Yufan Bio, a subsidiary of Yinming Bio

The results of the study showed that of the 11 adult B-ALL patients treated with XYF19, 10 were patients with high tumor burden (Bone Marrow Blasts > 25%); during the treatment, the infusion dose of XYF19 was one lower than that of the marketed control product The proportion of patients with complete remission (CR) reached 73%; no subjects experienced cytokine release syndrome (CRS) reactions of grade 3 or higher, and no subjects experienced neurotoxic reactions

Liao Xuebin, director of Yinming Biotechnology and professor at the School of Pharmacy of Tsinghua University, believes that adult relapsed or refractory acute precursor B-cell lymphocytic leukemia has always been a difficult disease to treat

In this news, another clinically approved product, PRJ1-3024, is a small molecule inhibitor of HPK1 completely independently developed by Yinming Bio, which has a series of advantages such as better selectivity

It is hoped that Yinming Bio's new CAR-T cell therapy products and PRJ1-3024 will progress smoothly in clinical research and make more progress as soon as possible to provide patients with more clinical benefits

references:

[1] Two new breakthroughs have been achieved in the research and development of HPK1 targets of Yinming Bio: the clinical data of cell therapy was announced at the EHA CAR-T conference, and the small molecule drug was approved for clinical use in China.